PMID- 15732437
OWN - NLM
STAT- MEDLINE
DCOM- 20050609
LR  - 20161124
IS  - 0011-4162 (Print)
IS  - 0011-4162 (Linking)
VI  - 75
IP  - 1
DP  - 2005 Jan
TI  - Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and 
      efficacious 12-month treatment for melasma.
PG  - 57-62
AB  - This article describes a long-term, multicenter, open-label, 12-month study of 
      once-daily fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05% 
      (Tri-Luma Cream, hereinafter called TC [triple combination]) application in the 
      treatment of melasma. A total of 228 patients with facial melasma were enrolled 
      and treated; 173 patients (76%) completed the study. Most patients had 1 to 2 
      courses of treatment lasting approximately 6 months in total. TC cream showed a 
      favorable safety profile. only 3 patients (1%) withdrew from the study due to 
      treatment-related adverse events (AEs). A total of 129 patients (57%) experienced 
      at least one treatment-related AE. Most AEs were expected application-site 
      reactions that were mild and transient in nature and did not require remedial 
      therapy. There were no cases of skin atrophy or skin thinning and only 6 cases of 
      telangiectasia (5 mild and 1 moderate), most of which had improved by the end of 
      the study. Results of the efficacy assessments were positive, with both the 
      patient and the physician assessing melasma to be either completely or nearly 
      cleared by the end of the study in more than 90% of cases. In this study, a 
      once-daily application of TC cream over an extended period of 12 months showed no 
      notable safety concerns and offered an effective treatment for melasma.
FAU - Torok, Helen Mary
AU  - Torok HM
AD  - HMT Dermatology Associates, Inc, Medina, Ohio, USA. helenmtorok@aol.com
FAU - Jones, Terry
AU  - Jones T
FAU - Rich, Phoebe
AU  - Rich P
FAU - Smith, Stacy
AU  - Smith S
FAU - Tschen, Eduardo
AU  - Tschen E
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Cutis
JT  - Cutis
JID - 0006440
RN  - 0 (Antioxidants)
RN  - 0 (Drug Combinations)
RN  - 0 (Glucocorticoids)
RN  - 0 (Hydroquinones)
RN  - 0 (Keratolytic Agents)
RN  - 0 (Ointments)
RN  - 0CD5FD6S2M (Fluocinolone Acetonide)
RN  - 5688UTC01R (Tretinoin)
RN  - XV74C1N1AE (hydroquinone)
SB  - IM
MH  - Antioxidants/therapeutic use
MH  - Drug Combinations
MH  - Facial Dermatoses/*drug therapy
MH  - Female
MH  - Fluocinolone Acetonide/therapeutic use
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Hydroquinones/therapeutic use
MH  - Keratolytic Agents/therapeutic use
MH  - Male
MH  - Melanosis/*drug therapy
MH  - Middle Aged
MH  - Ointments
MH  - Treatment Outcome
MH  - Tretinoin/therapeutic use
EDAT- 2005/03/01 09:00
MHDA- 2005/06/10 09:00
CRDT- 2005/03/01 09:00
PHST- 2005/03/01 09:00 [pubmed]
PHST- 2005/06/10 09:00 [medline]
PHST- 2005/03/01 09:00 [entrez]
PST - ppublish
SO  - Cutis. 2005 Jan;75(1):57-62.